8-K 1 a05-11357_18k.htm 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported):  June 23, 2005

 

NITROMED, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

 

 

 

Delaware

 

000-50439

 

22-3159793

(State or Other Jurisdiction of
Incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)

 

 

 

 

 

125 Spring Street

 

 

 

 

Lexington, Massachusetts

 

 

 

02421

(Address of Principal Executive
Offices)

 

 

 

(Zip Code)

 

 

 

 

 

Registrant’s telephone number, including area code: (781) 266-4000

 

 

 

 

 

 

 

 

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o                 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Item 8.01.                                          Other Events.

 

On June 23, 2005, NitroMed, Inc. (“NitroMed”) issued a press release announcing that the U.S. Food and Drug Administration approved NitroMed’s product candidate BiDilâ(isosorbide dinitrate/hydralazine hydrochloride) for the treatment of heart failure in black patients.  The full text of NitroMed’s press release regarding the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference.

 

Item 9.01.                              Financial Statements and Exhibits.

 

(c)                                  Exhibits

 

Exhibit
No.

 

Description

99.1

 

Press release of NitroMed, Inc. dated June 23, 2005

 

1


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 28, 2005

NITROMED, INC.

 

 

 

By:

/s/ Lawrence E. Bloch, M.D., J.D.

 

 

 

Lawrence E. Bloch, M.D., J.D.

 

 

Chief Financial Officer, Chief
Business Officer, Treasurer and
Secretary

 

2


 

EXHIBIT INDEX

 

Exhibit
No.

 

Description

99.1

 

Press release of NitroMed, Inc. dated June 23, 2005

 

4